CN1314909A - 具有抗HIV活性的d4T的磷酸芳基酯衍生物 - Google Patents

具有抗HIV活性的d4T的磷酸芳基酯衍生物 Download PDF

Info

Publication number
CN1314909A
CN1314909A CN99810072A CN99810072A CN1314909A CN 1314909 A CN1314909 A CN 1314909A CN 99810072 A CN99810072 A CN 99810072A CN 99810072 A CN99810072 A CN 99810072A CN 1314909 A CN1314909 A CN 1314909A
Authority
CN
China
Prior art keywords
compound
composition
hiv
group
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN99810072A
Other languages
English (en)
Chinese (zh)
Inventor
F·M·乌昆
R·维格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Parker Hughes Cancer Center
Original Assignee
Parker Hughes Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Parker Hughes Cancer Center filed Critical Parker Hughes Cancer Center
Publication of CN1314909A publication Critical patent/CN1314909A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
CN99810072A 1998-06-29 1999-06-29 具有抗HIV活性的d4T的磷酸芳基酯衍生物 Pending CN1314909A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/107,716 US6030957A (en) 1998-06-29 1998-06-29 Aryl phosphate derivatives of d4T having anti-HIV activity
US09/107716 1998-06-30

Publications (1)

Publication Number Publication Date
CN1314909A true CN1314909A (zh) 2001-09-26

Family

ID=22318071

Family Applications (1)

Application Number Title Priority Date Filing Date
CN99810072A Pending CN1314909A (zh) 1998-06-29 1999-06-29 具有抗HIV活性的d4T的磷酸芳基酯衍生物

Country Status (14)

Country Link
US (7) US6030957A (enExample)
EP (1) EP1090018B1 (enExample)
JP (1) JP2002519355A (enExample)
KR (1) KR20010071673A (enExample)
CN (1) CN1314909A (enExample)
AT (1) ATE277940T1 (enExample)
AU (1) AU4846999A (enExample)
BR (1) BR9911685A (enExample)
CA (1) CA2336285A1 (enExample)
DE (1) DE69920696T2 (enExample)
HU (1) HUP0102527A3 (enExample)
IL (1) IL140388A0 (enExample)
NO (1) NO20006685L (enExample)
WO (1) WO2000000501A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103403014A (zh) * 2011-01-03 2013-11-20 南京迈勒克生物技术研究中心 O-(经取代的苯甲基)氨基磷酸酯化合物及其治疗用途

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6030957A (en) * 1998-06-29 2000-02-29 Wayne Hughes Institute Aryl phosphate derivatives of d4T having anti-HIV activity
US7144874B2 (en) * 2002-10-25 2006-12-05 Parker Hughes Institute Aryl phosphate derivatives of d4T having activity against resistant HIV strains
US20070015733A1 (en) * 1998-06-29 2007-01-18 Parker Hughes Institute Aryl Phosphate Derivatives of d4T having Activity Against Resistant HIV Strains
WO2000056750A1 (en) * 1999-03-19 2000-09-28 Parker Hughes Institute One pot synthesis of 5'-hydroxy phosphorylated nucleoside derivatives, and compounds formed thereby
US6825177B2 (en) * 2000-10-30 2004-11-30 Parker Hughes Institute Aryl phosphate derivatives of d4T with potent anti-viral activity
PT1334108E (pt) * 2000-11-13 2005-08-31 Parker Hughes Inst Derivados arilfosfato da d4t
EP1513865A4 (en) * 2002-05-28 2006-05-03 Univ Minnesota USE OF CRISP POLYPPETIDES AS SPEECH CAPACITATION CONTACEPTIVES AND INHIBITORS
US20030236218A1 (en) * 2002-06-12 2003-12-25 Uckun Fatih M. Aryl phosphate derivatives of d4T with selective activity against adenovirus and HIV
US20040076931A1 (en) * 2002-10-18 2004-04-22 Cashflow Technologies, Inc. Educational interactive games
US20040077607A1 (en) * 2002-10-21 2004-04-22 Uckun Fatih M. Aryl phosphate derivatives of d4T with potent anti-viral activity against hemorrhagic fever viruses
GB0401088D0 (en) 2004-01-19 2004-02-18 Univ Cardiff Phosphoramidate derivatives
US20070265222A1 (en) * 2004-06-24 2007-11-15 Maccoss Malcolm Nucleoside Aryl Phosphoramidates for the Treatment of Rna-Dependent Rna Viral Infection
WO2006026656A1 (en) * 2004-08-31 2006-03-09 Parker Hughes Institute Cytotoxic nucleoside analog compound 003 for treating cancer
EP1827460A4 (en) * 2004-12-09 2012-03-14 Univ Minnesota NUCLEOSIDE WITH ANTIVIRAL AND ANTI-CANCER EFFECT
KR20080003789A (ko) * 2005-03-09 2008-01-08 더 리전츠 오브 더 유니버시티 오브 캘리포니아 나노복합체막 및 이의 제조 및 사용 방법
US7892618B2 (en) * 2005-03-21 2011-02-22 Sony Corporation Deterring theft of optical media
GB0623493D0 (en) * 2006-11-24 2007-01-03 Univ Cardiff Chemical compounds
WO2010108140A1 (en) * 2009-03-20 2010-09-23 Alios Biopharma, Inc. Substituted nucleoside and nucleotide analogs
WO2012040127A1 (en) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs
EP2794630A4 (en) 2011-12-22 2015-04-01 Alios Biopharma Inc SUBSTITUTED PHOSPHORTHIOAT NUCLEOTIDE ANALOGUE
NZ631601A (en) 2012-03-21 2016-06-24 Alios Biopharma Inc Solid forms of a thiophosphoramidate nucleotide prodrug
NZ630805A (en) 2012-03-22 2016-01-29 Alios Biopharma Inc Pharmaceutical combinations comprising a thionucleotide analog
AU2014250762A1 (en) 2013-04-12 2015-10-29 Achillion Pharmaceuticals, Inc. Highly active nucleoside derivative for the treatment of HCV

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4707362A (en) 1985-02-15 1987-11-17 Biotek, Inc. Sustained release composition
US4841039A (en) 1986-05-01 1989-06-20 Emory University 2',3'-dideoxy-5-substituted uridines and related compounds as antiviral agents
US4983393A (en) 1987-07-21 1991-01-08 Maximed Corporation Intra-vaginal device and method for sustained drug release
JPH06189998A (ja) 1992-11-06 1994-07-12 C & Co:Yugen コンド―ム
WO1994014831A1 (en) 1992-12-18 1994-07-07 The University Of Alberta Dihydropyrimidine nucleosides with antiviral properties
ZA947572B (en) 1993-09-29 1995-09-28 Hampton Roads Medical College Contraceptive compositions
US5672698A (en) * 1993-11-15 1997-09-30 Bristol-Myers Squibb Co. Preparation of 2',3'-didehydro-3'-deoxythymidine from 5-methyluridine
US5659023A (en) * 1995-02-01 1997-08-19 Gilead Sciences, Inc. Nucleotide analogues
GB9505025D0 (en) * 1995-03-13 1995-05-03 Medical Res Council Chemical compounds
AU723081B2 (en) 1996-05-09 2000-08-17 Infectio Recherche Inc. Formulation for use in the prevention of pathogen induced diseases including HIV and HSV
US6030957A (en) * 1998-06-29 2000-02-29 Wayne Hughes Institute Aryl phosphate derivatives of d4T having anti-HIV activity

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103403014A (zh) * 2011-01-03 2013-11-20 南京迈勒克生物技术研究中心 O-(经取代的苯甲基)氨基磷酸酯化合物及其治疗用途
CN103403014B (zh) * 2011-01-03 2016-07-06 河南美泰宝生物制药有限公司 O-(经取代的苯甲基)氨基磷酸酯化合物及其治疗用途

Also Published As

Publication number Publication date
WO2000000501A1 (en) 2000-01-06
HUP0102527A3 (en) 2002-04-29
DE69920696D1 (de) 2004-11-04
CA2336285A1 (en) 2000-01-06
US7071176B2 (en) 2006-07-04
ATE277940T1 (de) 2004-10-15
DE69920696T2 (de) 2006-03-02
IL140388A0 (en) 2002-02-10
NO20006685L (no) 2001-02-28
NO20006685D0 (no) 2000-12-28
KR20010071673A (ko) 2001-07-31
JP2002519355A (ja) 2002-07-02
BR9911685A (pt) 2001-12-18
US6503890B1 (en) 2003-01-07
US6030957A (en) 2000-02-29
US6350736B1 (en) 2002-02-26
US6537975B1 (en) 2003-03-25
US6528495B1 (en) 2003-03-04
US6670336B1 (en) 2003-12-30
AU4846999A (en) 2000-01-17
HUP0102527A2 (hu) 2001-12-28
US20040171577A1 (en) 2004-09-02
EP1090018B1 (en) 2004-09-29
EP1090018A1 (en) 2001-04-11

Similar Documents

Publication Publication Date Title
CN100343268C (zh) β－2′－或3′－卤代核苷
Balakrishna Pai et al. Inhibition of hepatitis B virus by a novel L-nucleoside, 2'-fluoro-5-methyl-beta-L-arabinofuranosyl uracil
CN103403014B (zh) O-(经取代的苯甲基)氨基磷酸酯化合物及其治疗用途
Nair et al. Antiviral activities of isometric dideoxynucleosides of D-and L-related stereochemistry
Eldrup et al. Structure− activity relationship of purine ribonucleosides for inhibition of hepatitis C virus RNA-dependent RNA polymerase
US8895531B2 (en) 2′-fluoronucleoside phosphonates as antiviral agents
US6503890B1 (en) Aryl phosphate derivatives of d4T having anti-HIV activity
Meier et al. cyclo Sal-Pronucleotides of 2 ‘, 3 ‘-Dideoxyadenosine and 2 ‘, 3 ‘-Dideoxy-2 ‘, 3 ‘-didehydroadenosine: Synthesis and Antiviral Evaluation of a Highly Efficient Nucleotide Delivery System
US20140212382A1 (en) Purine monophosphate prodrugs for treatment of viral infections
Meier et al. cyclo Sal-Pronucleotides of 2 ‘-Fluoro-ara-and 2 ‘-Fluoro-ribo-2 ‘, 3 ‘-dideoxyadenosine as a Strategy to Bypass a Metabolic Blockade
JP2005503358A5 (enExample)
WO2017197377A1 (en) Peptidomimetics for the treatment of norovirus infection
McGuigan et al. Phosphoramidate ProTides of 2′-C-methylguanosine as highly potent inhibitors of hepatitis C virus. Study of their in vitro and in vivo properties
JPH0780898B2 (ja) 抗ウイルスヌクレオシド
Choi et al. Structure− activity relationships of (e)-5-(2-bromovinyl) uracil and related pyrimidine nucleosides as antiviral agents for herpes viruses
Krecmerova et al. Synthesis of ester prodrugs of 9-(S)-[3-hydroxy-2-(phosphonomethoxy) propyl]-2, 6-diaminopurine (HPMPDAP) as anti-poxvirus agents
Kim et al. Synthesis, anti-hepatitis B virus and anti-hepatitis C virus activities of 7-deazaneplanocin A analogues in vitro
EP1768991A1 (en) Process for the preparation of a1-adenosine receptor agonists
Nguyen-Ba et al. Design and SAR study of a novel class of nucleotide analogues as potent anti-HCMV agents
US11618765B2 (en) Broad-spectrum antiviral nucleoside derivatives
Wang et al. Recent advances in carbocyclic nucleosides: Synthesis and biological activity
Bryant et al. Antiviral β-L-nucleosides specific for hepatitis B virus infection
Sommadossi Antiviral ß-L-Nucleosides Specific for Hepatitis B Virus Infection
CN1465574A (zh) L-核苷衍生物及其用途
HK1195317A (en) Purine monophosphate prodrugs for treatment of viral infections

Legal Events

Date Code Title Description
C06 Publication
C10 Entry into substantive examination
PB01 Publication
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication